

Adult Intravenous Iron Administration Standard Orders (for emergency department & outpatient clinics)

FOR NEPHROLOGY & ONCOLOGY PATIENTS – see Manitoba Renal Program www.kidneyhealth.ca or CCMB ARIA

*These orders are to be used as a guideline and do not replace sound clinical judgement and professional practice standards.
Patient allergy and contraindications must be considered when completing these orders.*

Automatically activated (If not in agreement with an order cross out and initial). Requires a check(✓) for activation

Allergies: Unknown No Yes (describe) _____

Height (cm): _____ **Weight (kg):** _____

INDICATION (indicate rationale for IV iron: check (✓) appropriate box(es))

- INDICATION (refer to table on page 2) _____
- Clinically significant anemia (Hgb less than 90 g/L) at risk of imminent transfusion
- OR**
- Hgb less than 110 g/L: date _____ result _____
- AND**
- Ferritin less than 20 mcg/L: date _____ result _____
- OR**
- Iron/transferrin saturation less than 16% within the last 4 weeks: date _____ result _____
- AND (one of the following):**
- Intolerance to at least 2 forms of oral iron: name _____ date _____ reaction _____
name _____ date _____ reaction _____
- Inadequate response to an adequate trial of oral iron (see criteria on page 2)
- Progressive anemia (decreased Hgb by greater than 10 g/L) despite oral iron supplementation
- Other: _____

MEDICATION ORDERS

Select one of the 2 regimens:

- ferric derisomaltose** (Iron isomaltoside Monoferric)
 - No test dose is required.
 - Check one(✓):
 - ferric derisomaltose _____ mg (for doses less than or equal to 1000 mg) IV in 100 mL normal saline at 170 mL/hour for ten minutes. If tolerated, increase to 340 mL/hour (total infusion time approximately 25 minutes)
 - ferric derisomaltose _____ mg (for doses greater than 1000 mg but no more than 1500 mg) IV in 100 mL normal saline at 120 mL/hour for ten minutes. If tolerated, increase to 240 mL/hour (total infusion time approximately 35 minutes)
 - ferric derisomaltose 500 mg undiluted IV over 2 minutes
- Iron Sucrose (Venofer)**
 - No test dose is required.
 - Check one (✓):
 - Iron sucrose 100 mg IV in 100 mL normal saline infused over 15 minutes
 - Iron sucrose 200 mg IV in 100 mL normal saline infused over 30 minutes
 - Iron sucrose 300 mg IV in 250 mL normal saline infused over 1.5 hours

Frequency and Duration for Recurrent Doses: (refer to dosing table on page 2)

- No repeat
- Repeat the above IV dose every _____ day(s) x _____
- Other frequency/duration _____

GENERAL ORDERS

- Admit & follow-up with _____ (prescriber)
- Place patient in a reclining or semi-reclining position during infusion and during 30-minute monitoring period.
- Vital signs:
 - Monitor blood pressure and heart rate:
 - Prior to start of infusion, then every 30 minutes
- Notify physician:
 - Immediately should patient have anaphylactic type reaction (dyspnea, angioedema and urticaria)
 - Laboratory (pre-iron administration). Check one or more (✓):
 - No current laboratory studies required
 - CBC
 - Ferritin
 - TSTAT (Percent transferrin saturation; report includes iron & TIBC)
 - Other: _____
- Repeat laboratory studies 4 to 8 weeks after IV administration
- May discontinue monitoring patient 30 minutes post IV iron dose
 - Vital signs stable
 - No signs of symptoms of hypersensitivity
 - No other nursing concern
- If an anaphylactic reaction occurs
 - Stop infusion
 - Initiate Anaphylaxis Standard Orders CLI.5110.SG.009.FORM.02
 - Notify prescriber _____

PRESCRIBER'S SIGNATURE: _____ PRINTED NAME: _____ Date _____ Time _____

Order Transcribed
Date: _____ Time: _____ Init _____ FAX TO PHARMACY
Date: _____ Time: _____ Init _____

General indications and criteria for IV iron

<ul style="list-style-type: none"> Inadequate response to an adequate* trial of oral iron Gastrointestinal intolerance to at least 2 forms of oral iron Demonstrated non-adherence to oral iron Ongoing blood loss that exceeds the capacity of oral iron to meet requirements Inability to absorb oral iron (e.g. Celiac disease, Whipple's disease, inflammatory bowel disease, gastric surgery such as bypass or resection) Chronic kidney disease, pregnancy, elderly, patients undergoing chemotherapy or radiation Treatment of pre-operative iron deficiency anemia before high blood loss surgery
<p>*Adequate trial: duration of at least 3 months, adequate dose of 200 mg/day of elemental iron, 250 - 500 mg Vitamin C with each dose of iron to enhance absorption, administration on an empty stomach 1 hour before breakfast or at bedtime</p>

Oral Iron Products

Product (iron salt)	Elemental iron per tablet/capsule	Cost Estimate per Month	Strategies to improve tolerability:
Ferrous gluconate 300 mg	35 mg	\$	<ul style="list-style-type: none"> Take every other day (or Monday-Wednesday-Friday) 1 to 3 tablets based on patient tolerance (target 100 to 200 mg elemental iron/day) One dose per day preferably 1 hour before breakfast (take with food if not tolerated) Take with orange juice or 500 mg Vitamin C tablet (increases absorption) Take for a minimum of 3 months
Ferrous sulfate 300 mg	60 mg	\$	
Ferrous fumarate 300 mg	100 mg	\$	
Polysaccharide-iron complex 150 mg (e.g. FeraMAX, Polyride Fe)	150 mg	\$\$	

Dosage of IV iron

Iron	Usual Dose	Cost estimate for 1000 mg												
Iron Sucrose (Venofer)	<ul style="list-style-type: none"> Calculate "Iron Deficit" (total dose needed) using Ganzoni formula** Divide "Iron Deficit" into appropriate individual doses <p>Administer as total dose divided in increments of 100 to 300 mg per session every 2 to 3 days. Ex. Total Iron Deficit 1000 mg, consider: 200 mg IV x 5 doses</p>	\$\$\$\$												
Ferric derisomaltose (Iron Isomaltoside Monoferic)	<p>Ex. Total Iron Deficit 1000 mg, consider 1000 mg IV x 1 dose OR 500 mg IV x 2 doses</p> <p>OR simplified table below:</p> <table border="1"> <thead> <tr> <th>Hemoglobin (g/L)</th> <th>Less than 50 kg</th> <th>50 to less than 70 kg</th> <th>Greater than or equal to 70 kg</th> </tr> </thead> <tbody> <tr> <td>Greater than or equal to 100</td> <td>500 mg</td> <td>1000 mg</td> <td>*Dose 1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg</td> </tr> <tr> <td>Less than 100</td> <td>*Dose1: 500 mg Dose 2: 500 mg Total dose: 1000 mg</td> <td>*Dose1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg</td> <td>*Dose1: 1000 mg Dose 2: 1000 mg Total dose: 2000 mg</td> </tr> </tbody> </table> <p>*dose 1 and 2 given at least 7 days apart</p>	Hemoglobin (g/L)	Less than 50 kg	50 to less than 70 kg	Greater than or equal to 70 kg	Greater than or equal to 100	500 mg	1000 mg	*Dose 1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg	Less than 100	*Dose1: 500 mg Dose 2: 500 mg Total dose: 1000 mg	*Dose1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg	*Dose1: 1000 mg Dose 2: 1000 mg Total dose: 2000 mg	\$\$\$
Hemoglobin (g/L)	Less than 50 kg	50 to less than 70 kg	Greater than or equal to 70 kg											
Greater than or equal to 100	500 mg	1000 mg	*Dose 1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg											
Less than 100	*Dose1: 500 mg Dose 2: 500 mg Total dose: 1000 mg	*Dose1: 1000 mg Dose 2: 500 mg Total dose: 1500 mg	*Dose1: 1000 mg Dose 2: 1000 mg Total dose: 2000 mg											
<p>*Above are general dosing examples. Consult SHSS IV monograph for specific indicators, dosing and administration. Professionals familiar with dosing, administration and appropriate monitoring should only use parenteral iron.</p> <p>** Iron deficit (mg) = weight (kg) x [(target Hgb (g/L) – current Hgb) ÷ 10] x 2.145 + iron stores (mg) if desired (Use ideal body weight (IBW) for obese patients. Iron stores are 500 mg for patients greater than or equal to 35 kg (15 mg/kg for patients less than 35 kg)).</p>														

Monitoring of IV iron therapy

Patients receiving regular parenteral iron require monitoring of hematologic parameters and iron indices. Repeat laboratory studies should not be performed until 4 to 8 weeks after the completion of administration since IV iron interferes with most assays or iron studies.